<SEC-DOCUMENT>0001564590-20-047181.txt : 20201022
<SEC-HEADER>0001564590-20-047181.hdr.sgml : 20201022
<ACCEPTANCE-DATETIME>20201022091147
ACCESSION NUMBER:		0001564590-20-047181
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20201022
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201022
DATE AS OF CHANGE:		20201022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		201251855

	BUSINESS ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>achv-8k_20201020.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-8k_20201020.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): October 22, 2020 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90.49%;">
<tr>
<td style="width:27.28%;"></td>
<td style="width:0.56%;"></td>
<td style="width:32.38%;"></td>
<td style="width:0.56%;"></td>
<td style="width:29.72%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">033-80623</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">95-4343413</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="3" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia, Suite 1030</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vancouver, B.C., Canada </p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V6E 4H1</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (604) 210-2217 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;padding-Bottom:0.4pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;padding-Bottom:0.4pt;width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading symbol(s)</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;padding-Bottom:0.4pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.4pt;padding-Bottom:0.5pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value per share</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;padding-Bottom:0.5pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.4pt;padding-Bottom:0.5pt;width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACHV</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.5pt;padding-Bottom:0.5pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.5pt;padding-Right:0.5pt;padding-Top:0.4pt;padding-Bottom:0.5pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NASDAQ Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01.&nbsp;&nbsp;Regulation FD Disclosure</font><font style="font-weight:normal;">. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 22, 2020, Achieve Life Sciences, Inc. (the &#8220;Company&#8221;) issued a letter to its shareholders (the &#8220;Shareholder Letter&#8221;).&nbsp;&nbsp;A copy of the Shareholder Letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.&nbsp;&nbsp;The Shareholder Letter will also be available for viewing at the Company&#8217;s investor website.&nbsp;&nbsp;The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information in this Item&#160;7.01 of Current Report on Form&#160;8-K,&#160;as well as Exhibit 99.1, shall not be treated as &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.&nbsp;&nbsp;Financial Statements and Exhibits.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1<font style="margin-left:36pt;"></font><a href="achv-ex991_16.htm"><font style="text-decoration:underline;">Shareholder Letter, dated October 22, 2020.</font></a></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:8.06%;text-indent:0%;letter-spacing:-0.15pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:8.06%;letter-spacing:-0.15pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;">SIGNATURES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences, Inc<font style="font-weight:normal;color:#000000;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="font-size:11pt;"> October 22, 2020</font></p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Bencich</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">John Bencich</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer </p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>achv-ex991_16.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex991_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000001.jpg" title="" alt="" style="width:95px;height:105px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 22, 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Fellow Shareholders,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hope this letter finds you and your families safe and healthy. Given that we continue to live in unprecedented times, faced with uncertainty and unique challenges, John and I thought it was appropriate to reach out with an update on the company&#8217;s progress. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve remains committed to prioritizing the health and safety of our patients, health care providers, and employees. Like many of you, we have adjusted how we conduct business. Our teams continue to work remotely, we have restricted all non-essential travel, and we have implemented numerous safeguards for employees and stakeholders. This commitment extends to participants in our upcoming trials to mitigate against the potential impact of COVID-19. While this is not business as usual, we continue to make excellent progress advancing cytisinicline towards U.S. market approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the corporate development front, we recently <font style="text-decoration:underline;">announced</font> management changes that included internal promotions of two key executives. These changes have been planned for a long time and were expedited in part by the pandemic, which has restricted international travel for Rick Stewart and Dr. Anthony Clarke, co-founders of Achieve, who are both based in the United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The appointment of John Bencich as Chief Executive Officer and Dr. Cindy Jacobs as President and Chief Medical Officer reflects their contributions to the success of the company thus far. Rick Stewart will continue to serve as the Executive Chairman of the Board of Directors. Additionally, Rick will continue providing his expertise and leadership on strategic initiatives for the company, such as potential commercial partnering and registration of cytisinicline in European markets.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the last three years as Achieve&#8217;s Chief Financial and Operating Officer, John has led the financing activities which provided the capital to complete the successful Phase 2 ORCA-1 trial last year, and more recently, the funding to allow us to initiate the Phase 3 ORCA-2 trial. John has consistently demonstrated his leadership capabilities across all aspects of the business and has been instrumental in ensuring that Achieve continues to execute on its key objectives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000001.jpg" title="" alt="" style="width:95px;height:105px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under her stewardship, Dr. Cindy Jacobs has led the clinical development team at Achieve and has been responsible for the successful ORCA-1 Phase 2b trial and the planning and execution of the ORCA-2 Phase 3 trial that recently commenced.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our leadership has realigned, our management team remains steadfast in our mission and in our conviction that cytisinicline has great promise to change the lives of millions of smokers.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this regard, we are pleased to have recently announced <font style="text-decoration:underline;">the start of the Phase 3 ORCA-2 trial</font> that we expect<font style="color:#B5082E;"> </font>will enroll 750 smokers at 15 clinical trial locations throughout the United States. <font style="text-decoration:underline;">ORCA-2</font> is the first randomized, double-blind Phase 3 trial evaluating a new therapy for smoking cessation in over a decade. ORCA-2 is designed to evaluate the efficacy and safety of 3 mg cytisinicline given three times daily for 6 and 12-weeks compared to placebo. Importantly, the study will be considered successful if <font style="text-decoration:underline;">either or both</font> of the arms show an efficacy benefit. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a reminder, the Phase 2b <font style="text-decoration:underline;">ORCA-1</font> trial that we conducted in 250 U.S. smokers showed robust efficacy and a well-tolerated safety profile for cytisinicline, providing important insights to help us to optimize the design of the Phase 3 trial. In ORCA-2, we will evaluate the higher 3 mg dose for a longer treatment duration and utilize the simplified three times daily dosing regimen. We believe these modifications could lead to potentially increased quit rates and more durable efficacy results. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The confidence that we have in cytisinicline&#8217;s ability to help smokers quit comes not only from our own studies but from numerous clinical trials that have evaluated more than 10,000 smokers and have been conducted by external experts in the field of smoking cessation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most recently, the <font style="text-decoration:underline;">results</font> of the &#8220;RAUORA&#8221; trial that compared cytisinicline to Chantix&#174;, the market leader in smoking cessation, were presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual European Meeting. This was the first-ever head-to-head study comparing these two treatments and enrolled a total of 679 smokers. The trial met its primary endpoint of showing that cytisinicline was non-inferior to Chantix and also showed a trend towards superiority for cytisinicline. Smokers who received cytisinicline <font style="font-weight:bold;text-decoration:underline;">were one- and one-half times more likely to have quit smoking at six months</font> compared to those who received Chantix.&nbsp;&nbsp;Importantly, subjects on cytisinicline experienced <font style="font-weight:bold;text-decoration:underline;">significantly fewer side effects</font><font style="font-weight:bold;">, </font><font style="font-weight:bold;text-decoration:underline;">including significantly less nausea</font> than those subjects treated with Chantix.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000001.jpg" title="" alt="" style="width:95px;height:105px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Data</font> were also presented at this meeting that may help to explain why the mechanism of action is directly implicated in the differentiated side effect profiles of these two smoking cessation medications. Research from the University of Cambridge Department of Biochemistry elucidated the potential role of the 5-HT<sub style="font-size:85%; vertical-align:bottom">3 </sub>receptor activity in the development of Chantix side effects. By comparison to cytisinicline, this study showed that Chantix has a 2000-greater fold binding affinity to the 5-HT<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor, which is believed to be the cause of increased rates of nausea and vomiting that smokers can experience while on Chantix. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is widely documented that nicotine is one of the most addictive substances on the planet. Quitting smoking successfully often takes multiple attempts, which is why a new therapy with improved safety and tolerability is urgently needed. We believe and expect to confirm in our Phase 3 trials that cytisinicline can offer smokers a safe and effective new treatment and a renewed hope in their ability to quit. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we look to the future, our primary focus is enrollment and execution of our Phase 3 program in smoking cessation. We do, however, continue to explore opportunities for expansion into new therapeutic indications, digital health technologies, and audiences who may benefit from cytisinicline, specifically, users of vapes or e-cigarettes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk53492005"></a><a name="_Hlk53491217"></a>The use of e-cigarettes continues to grow, with most recent reports indicating nearly 14 million adult users in the United States alone.&nbsp;&nbsp;While e-cigarettes have been historically viewed as less harmf<a name="_Hlk53492005"></a>ul than combustible cigarettes, their long-term safety remains controversial. In a recent study that we conducted surveying <a name="_Hlk53491217"></a>approximately 500 users of nicotine vaping devices or e-cigarettes, approximately 73% of participants responded they intend to quit vaping within the next 3 to 12 months. Of those who intended to quit even sooner, within the next three months, more than half stated they would be <font style="font-weight:bold;text-decoration:underline;">extremely likely to try a new prescription product</font> to help them do so. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In partnership with leading smoking cessation and nicotine addiction experts, we have completed the development of a Phase 2 <font style="text-decoration:underline;">ORCA-V1</font> trial protocol to evaluate cytisinicline in this rapidly growing population of e-cigarette users. We are currently pursuing non-dilutive funding sources to help support this initiative. We believe that cytisinicline could be the first prescription drug to offer a new option for vape and e-cigarette users who are ready to quit their nicotine addiction for good.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000001.jpg" title="" alt="" style="width:95px;height:105px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding our capitalization, our current funding and cash position are strong. We had approximately $12.2 million as of <font style="text-decoration:underline;">June 30, 2020</font>, and secured an additional $14.8 million in proceeds, after commissions and offering expenses, from equity financings and warrant exercises during the third quarter. To that end, we recently terminated our At the Market (ATM) Offering Agreement with H.C. Wainwright &amp; Co., LLC, as we did not expect to utilize the facility going forward. The facility was terminated unused with no shares issued or sold. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In closing, thank you for your interest and continued support of Achieve. This is an exciting time for the company as we embark on our Phase 3 program that has the potential to impact the health and well-being of millions of smokers. We will continue to remain focused on our mission and appreciate your support as we make the important transition to Phase 3 development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely, </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.98%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000005.jpg" title="" alt ="" style="width:75px;height:75px;">&nbsp;&nbsp;<font style="margin-left:36pt;"><img src="g0ep5evosdkj000006.jpg" title="" alt="" style="width:95px;height:61px;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rick Stewart<font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; John Bencich</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;Executive Chairman<font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">Forward Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>This letter contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, <font style="Background-color:#FFFFFF;">the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline, the effectiveness and potential uses and benefits of cytisinicline, including but not limited to as an e-cigarette cessation product, and statements regarding the ability to secure any non-dilutive financing</font>. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that cytisinicline may not be effective in treating a larger breadth of diseases and addictions; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; impacts from the COVID-19 pandemic, including but not limited to impacts on Achieve&#8217;s ongoing and planned clinical trials; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0ep5evosdkj000001.jpg" title="" alt="" style="width:95px;height:105px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date</font><font style="font-size:10pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hereof, other than as may be required by applicable.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chantix&#174; is a registered trademark of Pfizer, Inc. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g0ep5evosdkj000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0ep5evosdkj000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 %$# 2(  A$! Q$!_\0
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M1*9HUC3Y?,!4'$9PTAP" &8\]3TGQ^,.F7'A7PM;QR&#2=,S'/(X+.K$1@$
M 9 @SGONZ#'.I^SCX82>\U/Q/<P;OL^+2T<[2 Y&9"!]X,%* 'CAV'/./,_B
M9K</B'XD:YJ-OY?D-<>5&T<@D618U$8<,."&";OQZGK0!Z)^S7IGF^(=<U;S
ML?9K1+;RMOWO-?=NSGC'DXQCG=VQS]'UXO\ LW6-O'X-U:_6/%U-J'DR/N/S
M(D:%1CIP9'_/V%>T4 %%%% !1110!'//#:V\MQ<2QPP1(7DDD8*J*!DDD\
M=Z^,/&.OW/C[QCJNM,TD=HB,T7F(Y$$"?+&I"[MA9BH_N^9)U .:^A_CGXH;
MP]\/IK2WDC%WJS_8P"Z[A$03*P4@[AM^0],>8#D'&?F2X^QVGA>T@3R)KZ^E
M-U+(,,UO&A:-(\]59CYC,IR"ODD=Z .L^%^I:1X1>_\ &>L+)++9(;?2[505
M-S<.IWD-G ")PV00!*IZ[0W+^(]2U?Q1?WGBG4UCS=W C+J BE@@PB+G+!5"
M@GG&5W'+#-/1H=+EU%#K-U/!81X>46T>^:49 V1@_*&.<Y8@  GDX5NT^)?C
M+PSXETOP[IGA?3;O3[/24F3RIXU48?9C&UV).58DGDDYY)- 'IGAG4_^%>?L
MW_VQ!#]EU.\\R2(3-M:2:20I'(JN"#B-5<*!AE3/<FOG,PLMNDY,>QW9 !(I
M;*@$Y7.0/F&"1@\XS@X[3QOX]_X2;P]X8T.S$\5CI&GQ13)(-OF7"H$9L!B"
MH"C:2 1N?UKE]3U:34X--A:V@@CT^T%K&(=WS#>\A9MS'YBTC$XP.> !0!]!
M_"'Q/X0\'?"N*;4?$%I!<7%Q)<7-LTP>5&+^6H6)07P51#T/4GITQ/B!\?OM
MMG<Z3X1BG@63Y&U20['VY(/E+U7(VD.2&&3\H.",/X>?!";QCHEKKU_K$=II
M]P^8X8(R\KJKLC@DX"'Y>#\_7D<8//Z]X7TR^^+,?A#PU'(EI'<1:>TZI)+(
M77 FE<$\E6WD[=JX3(P.: .;TG7/$'A:6*ZTN_OM.\_;,IC=D2<(S $K]V10
MP<<@C[P]:^XX)X;JWBN+>6.:"5 \<D;!E=2,@@C@@CO7BGQZ\%V<7@;2]3TV
MT\O^Q?+LR58?+:D;5#%OF;:^P#DXWL<<DCJ_@EK[:]\,K%96D:?3G:QD9D50
M0F"FW'4"-D&3@Y!Z]2 >B4444 ?+G[0NOMJ7CR+2%:3R-*MU4HR*!YL@#LRD
M<D%?*'/=3@=SY?JE^VI7[7#&38$2&)9&5F6*- D:DJJAB$51G SC/>KGBO6?
M^$A\6ZMJX>=X[N[DEB\\Y=8RQV*>3C"[1@' Q@<5Z9X2^!4WBCX?1:R]_)8:
MI<NTMK'*A,3PXPF\8#*68;@P+#800#F@#S_2OA_XOUI[=;#PYJ3I<IOBF> Q
MQ,NW<#YCX3!'0YYXQU%9>K:1+H\MO%-=6,\DL7FD6=TEP(_F9=K,A*[OEW8!
M/#+WX'HD_P +OBIH(ET73_M<NGW3E'%AJ&VWF+1Y;<I9<#:NTEU ) '.5SQ_
MC7P5J7@368=+U2>TFGEMUN%:U=F4*69<'<JG.4/;TH ZCX9?#;3?%6C:SX@\
M17EW9Z+IJ$>9:[=S,J[Y"<ACA5QQMYWC!X(/G]KI5]>V%]?V]M)):6"(]U,!
M\L0=PBY/J6/ Z\$] <?2?Q<N;/P)\'K?PUI3>5]IV6,0641R&-?FED(4#?NQ
MM?  )EYZX.!\.? ']K? ;7ML>^^US?);^3+AG\AOW*-N^5?WJ/G_ &7ZCL >
M;^$?'_C7P7IRW>FR3RZ(LI@\J[B:2T\S#-L!XV-\Q?"L">"<BKGP;\2>'/"G
MC&34O$,DD8-NT5O(+;S5B8\ER0=RG"[!M4Y\PY(&<Y>C>%_&NOSIX-MK&^BA
MANQ<3P7$311VTDB "28D?+\B<9YQG:"6(/N=Y^SUX4N=&M;>&:[M-0AM]DEW
M"Y*SR[0/,>-RV!N!.U2O4C/0@ ] U:STWQMX.OK*WN[2YL]0MY(H[F/;/&K<
M@.,'!*L,]>"O4$5X1^S?K<-IXEU;1I?+5[^W26)VD ):(GY%7^(E9&;@\!#Q
MZ9]_\*?B'\/;W^V/#MQ)>"-R!+I;-YI0.NT20D98,<$H-X^4YX&3Y_#K^M:-
MXU.O2M)'K4%ZUQ.)4,9,NXF175=I )+*RC'!(H ^XZ*Y_P#X3+2_^?77/_!#
M>_\ QFB@#Y4T+X7^)M6\8Q^'KK3;O3W#_P"DW$UNS1PI\WSY'!!\MPISAB,
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3E"1E3E1R/0>E7** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g0ep5evosdkj000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0ep5evosdkj000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ & # 2(  A$! Q$!_\0
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HU"JHP !@"EHAZL;!!';0K#$NU%& *DHHJ2@HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g0ep5evosdkj000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0ep5evosdkj000001.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !I %X# 2(  A$! Q$!_\0
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MC.[A)YG)1FD[/EE_9UI6>FC>K7H_&7 ,6VEF[O&W,EAHMQVW7M[K9[]EV/\
M(C^SW_\ SYW7_@/+_P#&Z/L]_P#\^=U_X#R__&Z_UUM*T+X:Z[I=GKFB:/X%
MUC1=0MEO+#6-*T[0=0TN]M'!*75IJ%I%-:7-LP!*S0RO&P!P_I#H.D_"_P 4
MZ7;:YX9TWP!XBT6],XL]8T*Q\/ZOI=V;6XDM+D6VH6$<]I.;>[@GM9Q%,_E7
M$,L,FV2-T"?C=)7OPTUROEE?-)+EEK[LKY=[LO=EH]59W7NL:X 6G_"O+575
ML+'5+ENU^_U7FO[I_D7_ &>__P"?.Z_\!Y?_ (W4JV.J/TT^^/LMI.QY]A%S
M^%?ZY>BZ7\+?$EM/>^'=-\ :_:6M]>:7=76B6?AW5;:UU33Y!#?Z=<3V*3Q0
M7UC-^ZO+.5UN+:3]W,D;\'A?^%H?LQVM_>:4?B'\!K;5--NY["_TT>+/A]#J
M-A?VDS6]U97ED=06YM;JUG22&XMIXHYH94>.2-74BFO&RK)R4.&)2E'=+,9R
M:]5'+KI?D2^ 812<LXM%VU>&BD]M$W779_<C_,^_8'_:N^*/[#/[3G@#X_\
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M+!X<D\+1"'Q=>VTUKIITN36-<;S;&VLX1/<B^*SSR.4AC1%W?!'PI_X)F?\
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M>HWL=K&XA%Q(%W'\AOV(/^"0%E^R%^UM\0/VB;OXP)X[\%K!\5-)_9\^$O\
MPBLVFVWP1T#XK>/#XQUBVL];FUV^@U"YBL&F\/[[/1M,%Q!=W<\DFR06X\?)
M<UP.$P>*6-KJ6,RK&5\SR6U.K5CBL7B<)4PE1<SAS4TL32RW'Q=?DYHX>HI)
M5)J+[,;A:]:M2]C3_<XNC#"XU-QBZ="G5C5;:4M7*E+$X=\C?*ZD&KQ3:X#_
M (.$X],L/V(O@[I+^%Y/$VDS?M@? +23X)TV"-Y?$6FPV7C.4^%K"U9HH7DU
M:TLSI5I;EXXR\Z(71>1Z#^P1\$/V7/%GC'QUJNC_ /!*#QY^Q7K6C>&;/3T\
M5?%'PCH>BP>,M+UG58KB\\/:)<:1XGU6YN);2ZT33M2U"*6SC@18[1Q=;R(W
M^H/^"DO[$GB?]NWX._#GX;>#OBW9?!CQ#\-_CKX%^.&E^+-0\$GQ[;3W_@31
M_%MCIVDR:&/$7AA5$FI>([/4S=R7MQ&JZ8UJ]C*MWYUOA?#WX#_\%,=$U.YF
M^('[?/PE\;Z2VG306UA8_L@Z+X;NH=2:ZM)(;Y[^T^)-P)H8K6*\MVM/LR"1
M[F.;S08-KU2S'#3X6PV71S&AAL7'$X^I7I5<1G-&3C6J8-T7&C@Z%3 XI35&
MI?ZQ+FIK9)N+)EAZO]J5:\\/4JT94</&G.-/!SCS0C5Y^9UIJO3<7)6]G'ED
MWJW9H]1_9>\<V/B']C+X:K'XOL=7\76WP"T^?45BURWO]?MKJU\+&$SWZ)=2
MZC#<03+$KS3[)4FV[V$F*^>9D\0>/_"'_!./0)=(TOQ_-XK^".I^(==\/^,_
M%FO>'M#UZ]T[X1> ;G^UM8U+2M*\07=YJ-C<:E<7-J;G3+HR3W5P3/"97D/$
M_L7?\E*\8_\ 9,O%?_I=H]?<_@O_ (^/V3?^R5Z[_P"H1X1K\*RVI/.,FRJ5
M5NDE1R_!U(QM456.'S?)U*I)5%*+E6C3E&491G%*HTU)*S_H7.IT>'.*,_EA
MJ"KO$XS.<VH.<W0GA9YCPWQ0X485<-&E5Y<+5K4ZM.=*="3E1C;V<FIP\@_:
M&M)K'XF_LN^$9--\"0Z(O@7XNO?^#_%_C[7?"WP]COM!MOA9#INW6;72IY]4
MN]"^U7EMH#W^BQ2O;W-[*$LVFEC;[MT4Q2^&],%O+90PMH]HL4ND7QU'3X4%
MG&JMIVI31I]NM(0";2\FA0W$:)-)&I=D'Y]_\%"?^/;X6_\ 7UXP_P#1&@U]
M>?!7_DA/P^_[)_I/_IHKW,MK+^WL\PG(K0A@:W/[J=I87"4E37+",E%)2D_?
M<;R?)&%VW\GG=!U>#>$,Q=22E*IF6%E3<JLU*<\TQN)GB).I5E%U)>VC3;]F
MIRC2BZE2I[JA\M_ &]@^&?C&\^$N/"OQ(^(FJ_#;Q7XST3XS>%O%5[X@O/B%
M9Z%KFGQ$?%:QN9]0E\->)+V^\0Z4VFWL6I:OH6JI%K,>BR:/'9KH[]!^R79?
M"[Q?X#^'WQ!\0ZW:^*OCS=V:77C[4O%.OW%SXWT+XD20SKXN\,MH5_?^=X8A
MT#4GU#2K'PS9:?96.G:=:P_9[5HL7,WF'_!/G_D-_&K_ +"NF?\ I5JU<F__
M "D.LO\ K_G_ /4<N*\?!8E4Z615W1IU*%7,,3E]#"U$I1PL9U*3I5XU+)U<
M11>'DHUJD'5E"LXRJ<_M*E7ZS-,)]:Q_%^5QQ&(PV,PV3X'.\7FF'J2A+,)X
M; U9XC!3PU[8? XR.9T>;"8>O#"T:F"C*&'=*=&AA>L^)7BS4V_9\^*$;ZDD
MTZ_MM:;X/']LZ]J&C::VEW'[2?A-I-&U36[43W>E>'KC2+B73[XP12QV^DRS
MQ);21?N6Z[XWZ"U[^S?X8\->&-8TSP'+XC^.GP>T*ZUCX.^/-6UR/2?[?^)O
MAO2Y;O2_%$]II=_)>QQW-O-/:S6J6NZ-;:5)[5V5YOCO_P F\_&7_LM>H_\
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MHT^FZBVJ6,OAB&PL[+0X+?[':V%O!;(1[%9?\G&:]_V1[P]_ZE^N5\">"?\
ME(-JW_80\4_^F#4J[7*K@<9EL<1-9@ZF88O 0GB(VE23K4)T<0O>G%XFG3C[
M.I4M'VK;G!44Y4WYT(X;.,!GU/ T9Y%R\/Y=GU98"K^[Q$J67U?KF75(*G3E
M_9V)Q&)=;#T/:M82$%1JO&M4ZM+VC]EZ*RU'X@_$K7M8M?AW>:^GQK_:"TS3
MM?N/'>JWWQ4%GIWQ/\6:78Z9)X4N[!K*TT:QT>%;"R^S:L1!I%M9F*U6,>7%
MY^WBSP]^SMX]UM?&NG:1\:K_ ,:ZI\0];TSXB>"?%M]J/Q+BT^;Q=8WS^$/&
M_A*2_E@M--\,)J5AH>E:KHVIII-O%H]KIYT+1[B;9+Q_PP_Y/BUK_LH'Q*_]
M \05T_[,W_)QW[0W_83UW_U*A7DT<3*>%P-*E&%+$0S;'8:GB94Z55)Q5.=6
MK4P[IQI59U8IP4Y?OJ>DHUW[T9_18S#TJ&/SG%XOVN+R^MPQDN9U\MIXBOA)
CRC5JU</AL+1S"G4J8C#4<+4J.LZ5**P>(?N5,&G&E.E__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
